These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1752152)

  • 41. Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.
    Sheehan MT; Nippoldt TB
    Pituitary; 2000 Dec; 3(4):227-30. PubMed ID: 11788010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
    Giustina A; Bonadonna S; Bugari G; Colao A; Cozzi R; Cannavo S; de Marinis L; Degli Uberti E; Bogazzi F; Mazziotti G; Minuto F; Montini M; Ghigo E
    Eur J Endocrinol; 2009 Aug; 161(2):331-8. PubMed ID: 19465485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical experience of octreotide in the treatment of acromegaly.
    Chang TC; Chang CC; Tsai KS; Huang TS; Tsai WY; Lin MH; Chen FW
    J Formos Med Assoc; 1992 Jun; 91(6):595-600. PubMed ID: 1358345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly.
    Tolis G; Yotis A; del Pozo E; Pitoulis S
    J Neurosurg; 1986 Jul; 65(1):37-40. PubMed ID: 2872284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
    Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE
    J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones.
    Veysey MJ; Thomas LA; Mallet AI; Jenkins PJ; Besser GM; Wass JA; Murphy GM; Dowling RH
    Gut; 1999 May; 44(5):675-81. PubMed ID: 10205204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide.
    Radetti G; Gentili L; Paganini C; Messner H
    Eur J Pediatr; 2000 Jul; 159(7):550. PubMed ID: 10923237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of small doses of somatostatin analog, octreotide, on gallbladder contractility in normal Chinese adults.
    Zhu XF; Shi YF; Qin-Dai ; Zhang JX; Harris AG
    Dig Dis Sci; 1992 Jan; 37(1):105-8. PubMed ID: 1345817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gall stones and treatment with octreotide for acromegaly.
    BMJ; 1989 Nov; 299(6708):1162-3. PubMed ID: 2513036
    [No Abstract]   [Full Text] [Related]  

  • 57. Proceedings of the discussion, "Tolerability and safety of Sandostatin".
    Wass JA; Popovic V; Chayvialle JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):80-2. PubMed ID: 1518439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Octreotide stimulates Ca++ secretion by the gallbladder: a risk factor for gallstones.
    Moser AJ; Giurgiu DI; Morgenstern KE; Abedin ZR; Roslyn JJ; Abedin MZ
    Surgery; 1999 May; 125(5):509-13. PubMed ID: 10330939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of non-steroidal anti-inflammatory drugs on formation of gallbladder stones.
    Minocha A; Greenbaum DS; Gardiner J
    Vet Hum Toxicol; 1994 Dec; 36(6):514-6. PubMed ID: 7900267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gall stones induced by octreotide.
    Catnach SM; Wass JA; Anderson JV; Besser M; Fairclough P; Hussaini H; Dowling H
    BMJ; 1992 Aug; 305(6848):313. PubMed ID: 1392873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.